Telix Net Borrowings vs Begin Period Cash Flow Analysis

TLX Stock

24.74 0.93 3.62%

Telix Pharmaceuticals financial indicator trend analysis is much more than just breaking down Telix Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Telix Pharmaceuticals is a good investment. Please check the relationship between Telix Pharmaceuticals Net Borrowings and its Begin Period Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Net Borrowings vs Begin Period Cash Flow

Net Borrowings vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Telix Pharmaceuticals Net Borrowings account and Begin Period Cash Flow. At this time, the significance of the direction appears to have strong relationship.

The correlation between Telix Pharmaceuticals' Net Borrowings and Begin Period Cash Flow is 0.67. Overlapping area represents the amount of variation of Net Borrowings that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Telix Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Telix Pharmaceuticals' Net Borrowings and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Borrowings of Telix Pharmaceuticals are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Net Borrowings i.e., Telix Pharmaceuticals' Net Borrowings and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.67

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Net Borrowings

The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Telix Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Telix Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Selling General Administrative is likely to gain to about 82.9 M in 2024, despite the fact that Tax Provision is likely to grow to (2 M).

Telix Pharmaceuticals fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Other Current Liab	Other Liab	Net Tangible Assets	Non Currrent Assets Other	Other Assets	Good Will	Inventory
Common Stock Shares Outstanding		0.74	0.66	0.53	0.61	-0.62	-0.84	0.72	0.68	0.76	0.68	0.74	0.92	0.93	0.77	0.62	0.69	0.77	0.65	0.64	0.86	-0.7	-0.24	0.64	0.94	0.61
Total Assets	0.74		0.98	0.9	0.96	-0.84	-0.91	0.98	0.73	0.98	0.73	0.99	0.88	0.79	0.98	0.96	0.98	0.99	0.98	0.98	0.92	-0.39	0.17	0.94	0.75	0.97
Total Current Liabilities	0.66	0.98		0.85	0.99	-0.77	-0.91	0.99	0.65	0.97	0.65	0.99	0.82	0.75	0.98	0.99	0.96	0.98	1.0	1.0	0.9	-0.41	0.17	0.96	0.69	1.0
Total Stockholder Equity	0.53	0.9	0.85		0.81	-0.87	-0.66	0.83	0.74	0.84	0.74	0.84	0.68	0.52	0.79	0.81	0.92	0.83	0.87	0.85	0.67	-0.03	0.34	0.83	0.54	0.85
Property Plant And Equipment Net	0.61	0.96	0.99	0.81		-0.74	-0.91	0.97	0.63	0.95	0.63	0.98	0.79	0.75	0.97	1.0	0.94	0.96	0.99	0.99	0.88	-0.36	0.19	0.95	0.67	0.98
Net Debt	-0.62	-0.84	-0.77	-0.87	-0.74		0.74	-0.73	-0.93	-0.72	-0.93	-0.76	-0.71	-0.65	-0.77	-0.74	-0.92	-0.84	-0.8	-0.79	-0.7	0.03	-0.34	-0.8	-0.55	-0.76
Retained Earnings	-0.84	-0.91	-0.91	-0.66	-0.91	0.74		-0.92	-0.69	-0.91	-0.69	-0.94	-0.92	-0.93	-0.97	-0.91	-0.89	-0.96	-0.9	-0.9	-0.97	0.6	0.02	-0.89	-0.84	-0.88
Accounts Payable	0.72	0.98	0.99	0.83	0.97	-0.73	-0.92		0.61	0.98	0.61	1.0	0.87	0.78	0.98	0.98	0.94	0.97	0.98	0.98	0.92	-0.49	0.05	0.93	0.75	0.98
Cash	0.68	0.73	0.65	0.74	0.63	-0.93	-0.69	0.61		0.61	1.0	0.65	0.64	0.7	0.67	0.63	0.8	0.74	0.68	0.67	0.63	-0.01	0.29	0.7	0.55	0.63
Non Current Assets Total	0.76	0.98	0.97	0.84	0.95	-0.72	-0.91	0.98	0.61		0.61	0.98	0.9	0.81	0.98	0.95	0.92	0.96	0.96	0.95	0.94	-0.52	0.08	0.9	0.81	0.94
Cash And Short Term Investments	0.68	0.73	0.65	0.74	0.63	-0.93	-0.69	0.61	1.0	0.61		0.65	0.64	0.7	0.67	0.63	0.8	0.74	0.68	0.67	0.63	-0.01	0.29	0.7	0.55	0.63
Net Receivables	0.74	0.99	0.99	0.84	0.98	-0.76	-0.94	1.0	0.65	0.98	0.65		0.88	0.8	0.99	0.98	0.96	0.99	0.99	0.98	0.93	-0.47	0.09	0.95	0.77	0.98
Common Stock Total Equity	0.92	0.88	0.82	0.68	0.79	-0.71	-0.92	0.87	0.64	0.9	0.64	0.88		0.92	0.91	0.79	0.83	0.9	0.8	0.8	0.97	-0.69	-0.17	0.74	0.91	0.78
Non Current Liabilities Total	0.93	0.79	0.75	0.52	0.75	-0.65	-0.93	0.78	0.7	0.81	0.7	0.8	0.92		0.86	0.75	0.75	0.84	0.73	0.73	0.94	-0.67	-0.1	0.72	0.91	0.7
Total Liab	0.77	0.98	0.98	0.79	0.97	-0.77	-0.97	0.98	0.67	0.98	0.67	0.99	0.91	0.86		0.97	0.95	0.99	0.97	0.97	0.97	-0.53	0.09	0.93	0.8	0.96
Property Plant And Equipment Gross	0.62	0.96	0.99	0.81	1.0	-0.74	-0.91	0.98	0.63	0.95	0.63	0.98	0.79	0.75	0.97		0.94	0.96	0.99	0.99	0.89	-0.38	0.18	0.95	0.67	0.99
Total Current Assets	0.69	0.98	0.96	0.92	0.94	-0.92	-0.89	0.94	0.8	0.92	0.8	0.96	0.83	0.75	0.95	0.94		0.98	0.97	0.97	0.87	-0.27	0.25	0.95	0.68	0.95
Common Stock	0.77	0.99	0.98	0.83	0.96	-0.84	-0.96	0.97	0.74	0.96	0.74	0.99	0.9	0.84	0.99	0.96	0.98		0.98	0.97	0.95	-0.45	0.11	0.95	0.79	0.96
Short Long Term Debt Total	0.65	0.98	1.0	0.87	0.99	-0.8	-0.9	0.98	0.68	0.96	0.68	0.99	0.8	0.73	0.97	0.99	0.97	0.98		1.0	0.88	-0.35	0.2	0.97	0.69	0.99
Other Current Liab	0.64	0.98	1.0	0.85	0.99	-0.79	-0.9	0.98	0.67	0.95	0.67	0.98	0.8	0.73	0.97	0.99	0.97	0.97	1.0		0.88	-0.36	0.2	0.96	0.66	1.0
Other Liab	0.86	0.92	0.9	0.67	0.88	-0.7	-0.97	0.92	0.63	0.94	0.63	0.93	0.97	0.94	0.97	0.89	0.87	0.95	0.88	0.88		-0.68	-0.05	0.84	0.89	0.86
Net Tangible Assets	-0.7	-0.39	-0.41	-0.03	-0.36	0.03	0.6	-0.49	-0.01	-0.52	-0.01	-0.47	-0.69	-0.67	-0.53	-0.38	-0.27	-0.45	-0.35	-0.36	-0.68		0.5	-0.3	-0.69	-0.36
Non Currrent Assets Other	-0.24	0.17	0.17	0.34	0.19	-0.34	0.02	0.05	0.29	0.08	0.29	0.09	-0.17	-0.1	0.09	0.18	0.25	0.11	0.2	0.2	-0.05	0.5		0.31	-0.24	0.2
Other Assets	0.64	0.94	0.96	0.83	0.95	-0.8	-0.89	0.93	0.7	0.9	0.7	0.95	0.74	0.72	0.93	0.95	0.95	0.95	0.97	0.96	0.84	-0.3	0.31		0.68	0.95
Good Will	0.94	0.75	0.69	0.54	0.67	-0.55	-0.84	0.75	0.55	0.81	0.55	0.77	0.91	0.91	0.8	0.67	0.68	0.79	0.69	0.66	0.89	-0.69	-0.24	0.68		0.63
Inventory	0.61	0.97	1.0	0.85	0.98	-0.76	-0.88	0.98	0.63	0.94	0.63	0.98	0.78	0.7	0.96	0.99	0.95	0.96	0.99	1.0	0.86	-0.36	0.2	0.95	0.63

Click cells to compare fundamentals

Telix Pharmaceuticals Account Relationship Matchups

Telix Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	233.4M	257.3M	282.2M	310.6M	323.7M	221.8M
Total Assets	102.6M	164.4M	109.8M	260.6M	398.3M	418.2M
Total Current Liabilities	10.6M	20.0M	38.0M	85.6M	157.4M	165.3M
Total Stockholder Equity	70.1M	79.0M	2.2M	80.0M	148.9M	156.4M
Property Plant And Equipment Net	1.9M	4.8M	6.3M	18.8M	30.5M	32.0M
Net Debt	(42.5M)	(75.7M)	(19.5M)	(105.9M)	(105.8M)	(100.5M)
Retained Earnings	(48.1M)	(93.0M)	(173.5M)	(272.8M)	(263.7M)	(250.5M)
Accounts Payable	7.0M	5.8M	11.9M	16.8M	32.8M	34.5M
Cash	44.6M	77.9M	22.0M	116.3M	123.2M	63.5M
Non Current Assets Total	43.9M	70.8M	62.3M	87.4M	173.5M	182.1M
Cash And Short Term Investments	44.6M	77.9M	22.0M	116.3M	123.2M	63.5M
Net Receivables	13.0M	14.2M	20.8M	39.4M	64.8M	68.0M
Liabilities And Stockholders Equity	102.6M	164.4M	109.8M	260.6M	398.3M	418.2M
Non Current Liabilities Total	21.3M	64.5M	68.2M	92.9M	92.0M	48.8M
Total Liab	31.9M	84.4M	106.2M	178.4M	249.4M	261.9M
Property Plant And Equipment Gross	1.9M	4.8M	8.4M	22.2M	36.3M	38.1M
Total Current Assets	58.7M	93.6M	47.5M	173.2M	224.8M	236.1M
Common Stock	115.9M	167.1M	170.8M	371.0M	446.3M	468.6M
Short Long Term Debt Total	2.1M	2.2M	2.5M	10.4M	17.4M	18.3M
Other Current Liab	3.2M	10.1M	19.3M	55.8M	100.5M	105.5M
Other Liab	20.3M	57.4M	67.8M	80.0M	92.0M	96.6M
Net Tangible Assets	28.1M	19.8M	(53.6M)	21.0M	18.9M	10.2M
Non Currrent Assets Other	(4.1M)	183K	(3.9M)	327K	586K	615.3K
Other Assets	82K	183K	212K	4.0M	4.6M	4.8M
Long Term Debt Total	1.6M	1.4M	1.9M	9.8M	11.3M	11.8M
Inventory	542K	633K	3.5M	8.5M	17.3M	18.2M
Other Current Assets	530K	859K	1.2M	9.1M	19.5M	20.5M
Other Stockholder Equity	2.2M	4.9M	4.8M	(562K)	(1.0)	(0.95)
Net Invested Capital	70.8M	79.4M	2.2M	83.3M	158.1M	166.0M
Short Long Term Debt	469K	264K	19K	964K	867.6K	911.0K
Accumulated Other Comprehensive Income	2.2M	4.9M	4.8M	(18.2M)	(33.7M)	(32.0M)
Net Working Capital	48.1M	73.7M	9.6M	87.7M	67.4M	56.9M
Short Term Debt	490K	767K	632K	641K	1.6M	874.9K
Intangible Assets	41.9M	59.2M	55.7M	59.0M	104.8M	56.3M
Property Plant Equipment	1.9M	4.8M	6.3M	18.8M	21.7M	22.7M
Long Term Debt	292K	95K	0.0	3.3M	8.2M	8.6M
Capital Stock	115.9M	167.1M	170.8M	371.0M	446.3M	246.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC